



UPMC South Side

A hospital of
University of Pittsburgh
Medical Center

RECEIVED
REGION 1

2006 FEB -6 PM 2: 55

2000 Mary Street
Pittsburgh, PA 15203-2095
412-488-5550

NMSB1

January 26, 2006

United States Nuclear Regulatory Commission
Region 1
475 Allendale Road
King of Prussia, Pennsylvania 19406-1415

RE: License No. 37-14013-01
UPMC South Side Hospital

03001983

To Whom It May Concern:

Please amend the above referenced license for our facility to reflect the following:

Please add Edward Kaliman, MD as an authorized user. For training and experience, please refer to the enclosed copy of NRC license 37-01626-04 from Sharon Regional Health System.

If you have any questions, please do not hesitate to contact me.

Sincerely,

Deborah E. Winn
Vice President, Operations
UPMC South Side Hospital

Enclosure

138366

NMOS/ONI MATERIALS-002

NRC FORM 374
(10-89)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 2 PAGES

MATERIALS LICENSE

Amendment No. 07

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee

1. Sharon Regional Health System
2. 740 East State Street
Sharon, Pennsylvania 16146

In accordance with letter dated
August 12, 1991,

3. License number: 37-01626-04 is amended in its entirety to read as follows:

4. Expiration date December 31, 1993

5. Docket or Reference No. 030-13670

6. Byproduct, source, and/or special nuclear material

7. Chemical and/or physical form

8. Maximum amount that licensee may possess at any one time under this license

- A. Any byproduct material identified in 10 CFR 35.100
- B. Any byproduct material identified in 10 CFR 35.200
- C. Any byproduct material identified in 10 CFR 35.300
- D. Any byproduct material identified in 10 CFR 31.11
- E. Uranium depleted in Uranium 235
- F. Any byproduct material identified in 10 CFR 35.500

- A. Any radiopharmaceutical identified in 10 CFR 35.100
- B. Any radiopharmaceutical identified in 10 CFR 35.200
- C. Any radiopharmaceutical identified in 10 CFR 35.300
- D. Prepackaged Kits
- E. Cadmium plated metal
- F. Any diagnostic source identified in 10 CFR 35.500

- A. As needed
- B. As needed
- C. As needed
- D. As needed
- E. 185 kilograms
- F. 1.5 curies per source not to exceed 4.5 curies total

9. Authorized use

- A. Any uptake, dilution and excretion procedure approved in 10 CFR 35.100.
- B. Any imaging and localization procedure approved in 10 CFR 35.200.
- C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300.
- D. In vitro studies.
- E. Shielding in a linear accelerator.
- F. Medical use of sealed sources included in 10 CFR 35.500 in compatible devices registered pursuant to 10 CFR 30.32(g).

NRC Form 374A
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 2 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number

37-01626-04

Docket or Reference number

030-13670

Amendment No. 07

(Continued)

CONDITIONS

10. Location of use: 740 East State Street, Sharon, Pennsylvania 16146.
11. Radiation Safety Officer: John C. Garriot, M.D.
12. Authorized Users: Material and Use:
- | | |
|-----------------------|----------------------------------------------------------------------------------------------------------------------|
| Allen H. Holt, M.D. | 35.100; 35.200; 35.300; 35.500
In vitro studies
Depleted uranium for shielding |
| Robert W. Allen, M.D. | 35.100; 35.200; 35.300; 35.500
In vitro studies
Depleted uranium for shielding |
| John C. Garriot, M.D. | 35.100; 35.200; 35.500
Iodine 131 for treatment of hyperthyroidism
and cardiac dysfunction
In vitro studies |
| Edward Kaliman, M.D. | 35.200 for cardiac imaging only |
13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material so that at no time is a quantity of radioactive material possessed in excess of a quantity which requires decommissioning funding in accordance with 10 CFR 30.35(a), 10 CFR 40.36(b) or 10 CFR 70.25(d).
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated June 20, 1988
B. Letter dated October 11, 1988
C. Letter dated June 20, 1990
D. Letter dated August 12, 1991

For the U.S. Nuclear Regulatory Commission

JAN 08 1992

Date

By

Nuclear Materials Safety Branch

Region I

King of Prussia, Pennsylvania 19406

CURRICULUM VITAE

Personal

Name: Edward G. Kaliman, M.D. F.A.C.C.

Address: [REDACTED]

Social Security Number: [REDACTED]

Marital Status: [REDACTED]

Date of Birth: [REDACTED]

Place of Birth: [REDACTED]

Office: 3000 Brownsville Road
Pittsburgh, PA 15227
(412) 882-0888

Education and Training

Undergraduate

1973 BS; Microbiology/Biophysics
University of Pittsburgh
Pittsburgh, PA

Graduate

1975 Research Microbiology
University of Pittsburgh
Pittsburgh, PA

1983 Medical School
New York Medical College
Valhalla, New York

Post-Graduate

1983 Internship; Internal Medicine
Allegheny General Hospital
Pittsburgh, PA

1984-1986 Residency; Internal Medicine
Allegheny General Hospital
Pittsburgh, PA

1985-1986 Chief Resident; Internal Medicine
Allegheny General Hospital
Pittsburgh, PA

1986-1989 Cardiology Fellowship
Allegheny General Hospital
Pittsburgh, PA

PERSONAL INFORMATION WAS REMOVED
BY NRC. NO COPY OF THIS INFORMATION
WAS RETAINED BY THE NRC.

1988-1989 **Angioplasty Fellowship**

1989-1990 **Nuclear Cardiology Fellowship - Junior Attending**

Research

1974-1975 **Graduate School of Public Health
University of Pittsburgh
Pittsburgh, PA**

 "Group B Streptococcal Infections in Neonates"

1974-1975 **Graduate School of Public Health
University of Pittsburgh-Magee Women's Hospital
Pittsburgh, PA**

 "Chlamydia Infections and Non-Gonoccal Vaginitis"

1987-1988 **Principal Investigator
Allegheny General Hospital
Pittsburgh, PA**

 "Circadian Anti-Ischemic Program (CAP)"

1987-1990 **A Double-Blind Comparison Study of Different Doses of Enoximone and Placebo in Patients
with Mild to Severe CHF, Co-Investigator**

1987-1991 **Boehringer Ingelheim Ltd.
Dipyridamole for Thallium-201 Myocardial Perfusion Investigator**

6-1988/10-1989 **Compassionate Use of MDL; Merrill Dow; Co-Investigator**

6-1988/10-1989 **A Comparative Placebo controlled Efficacy and Safety Study of Enoximone and
Dobutamine Including the Evaluation of the Pro Arrhythmic Effect of Enoximone and
Dobutamine; Merrill Dow Drug Company; Co-Investigator**

Jun-Aug 1988 **Clinical Evaluation of Cardiolite: New England Nuclear; Dupont; Co-Investigator**

Jan 1989-1990 **Open-Label Evaluation of Cardiotonic Activity of RGW-2938 by Radionuclide
Ventriculography in Congestive Heart Failure Patients; Protocol No. RGW-2938-108;
Rorer Central Research; Co-Investigator**

Jan 1989-1990 **An Evaluation of Hemodynamic Activity Following Acute Administration of Oral RGW-2938 in
Congestive Heart Failure; Protocol No. RGW-2938-107; Rorer Central Research; Co-Investigator**

Mar 1989-1990 **Open-Label Follow-Up Treatment with Oral RGW-2938 in Patients with Congestive Heart
Failure; Protocol No. 2938-106; Rorer Central Research; Co-Investigator**

Edward G. Kaliman, M.D. F.A.C.C.
Curriculum Vitae
Page Three

- May 1989-1991 A Double-Blind, Placebo-Controlled Study of the Effects of RGW-2938 on Exercise Performance in Ambulatory Heart Failure Patients; Protocol No. RGW-2938-105; Rorer Central Research; Co-Investigator
- Jun 1989-1991 Clinical Investigation of Tc-99m Teboroxime (Cardiotech) in Patients Undergoing Interventional Cardiac Procedures; Protocol #26742-5; Squibb; Co-Investigator
- 1989-1991 Evaluation of Cardiolite As An Adjunct in Conjunction with Stress Testing for the Diagnosis of Ischemic Heart Disease Using a Short Time Interval Between Rest and Stress Injections; E.I. Dupont deNemous and Company, Inc.; Co-Investigator
- Jun 1989-1991 Clinical Evaluation of Tc-99m Teboroxime (cardiotech) in Conjunction with Stress Testing for the Diagnosis of Ischemic Heart Disease; Protocol #26742-6; Squibb; Co-Investigator
- Jan 1989-1991 Dose Ranging of Oral RG-12152 in Patients with Congestive Heart Failure; Protocol #RG-12152-105; Rorer Central Research; Co-Investigator
- Jan 1989-1991 A Three-Month Double-Blind Safety Study of Oral RG-12152 Followed by Long-Term, Open-Label Treatment in Patient with Congestive Heart Failure; Protocol #RG-12152-107; Rorer Central Research; Co-Investigator
- June 1994 Principal Investigator - National Registry of Myocardial Infarction - South Side Hospital - June 1994 - until completion.

Medical License

- 1986 Commonwealth of Pennsylvania

Certifications

Board of Internal Medicine
Cardiovascular Diseases

American Board of Cardiovascular Diseases

Committees

- 1986-1989 Member of Allegheny General Hospital - CCU
- 1986-1989 Member of Allegheny General Hospital - MICU
- 1988-1989 Member of Allegheny General Hospital - CPR
- 1989-1991 Member of Allegheny General Hospital Transplant Committee
- 1989-1991 CCU/PCCU/6C Quality Assurance Committee
- 1991-1992 CCU/ICU Quality Assurance Committee - Sharon Regional Health System
- 1991-1992 Radiation Safety Committee - Sharon Regional Health System

1992	Cardiology and Catheterization Committee - South Side Hospital
1993	Renal Transplant Committee - Allegheny General Hospital
1993	Ethics Committee - South Side Hospital
1993	ICU/CCU Committee - South Side Hospital
June 1994	Critical Care Chairman - South Side Hospital of Pittsburgh
May 1994	Patient Management Chairman - Mercy Providence of Pittsburgh
April 1994	Physician Member to the Administration for the Joint Commission of Hospitals - South Side Hospital of Pittsburgh

Memberships

- American Medical Association
- Pennsylvania Medical Association
- Allegheny County Medical Association
- American Heart Association
- American College of Cardiology
- American College of Internal Medicine

Lectures and Community Education

3/90	Allegheny General Hospital - CCU - Teaching Attending Physicians
7/89	Medical and Cardiology - Cardiac Transplant

Abstracts

1990	EARLY REDISTRIBUTION OF THALLIUM FOLLOWING RAPID REVERSAL OF DIPYRIDAMOLE INDUCED CORONARY VASODILATATION Judith E. Orie, M.D., FACC, Tony G. Farah, M.D., Bruce E. Bartlett, B.S., Edward G. Kaliman, M.D., Angel R. Flores, M.D., Allegheny General Hospital, Pittsburgh, PA.
1990	PHARMACOKINETIC EFFECTS OF ANTIDEPRESSANT TREATMENT IN CARDIAC TRANSPLANT PATIENTS RECEIVING CYCLOSPORINE S. Nathan, M.D., J.E. Orie, M.d., G.J. Magovern, M.D., E.G. Kaliman, M.D., A.R. Flores, M.D.

Appointments

7/89-	Senior Attending Staff - Department of Cardiology & Internal Medicine Allegheny General Hospital
-------	-----------------------------------------------------------------------------------------------------

This is to acknowledge the receipt of your letter/application dated

1/26/2006, and to inform you that the initial processing which includes an administrative review has been performed.

☒ ATTEND. 37-14013-4
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

☐ Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 138366.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.